Global Vaccine Contract Development and Manufacturing Organization (CDMO) Market is poised to grow at 8-10% CAGR to reach $5 billion by 2025
The global Vaccine CDMO market is driven by increased demand from biotech vaccine developers & more selective outsourcing by pharmaceutical companies. Vaccine manufacturing is a highly complex process compared to small molecules. Currently, the penetration of CDMO is less than 20% of overall manufacturing value with ample opportunity for growth. There is growing trend towards outsourcing by the pharma and biotech industry for vaccine development and manufacturing. While biotech companies largely lack internal capabilities on process development and in-house manufacturing facilities qualified with GMP or BSL1 or BSL2 levels; big pharma companies mainly approach CDMOs for high volume vaccine manufacturing, risk mitigation and fill and finish activities. Also, large pharma may struggle to meet rising demand for new technology vaccines like viral vector and mRNA. Moreover, increased interest in development of newer vaccines like shingles, RSV, infectious diseases by smaller biot...